Mintaka Foundation receives Wellcome grant to get anti-HIV cream into clinic
This article was originally published in Scrip
The Mintaka Foundation for Medical Research in Switzerland has been awarded around CHF4.5 million ($4.2 million) from the UK's biomedical research charity the Wellcome Trust to meet the remaining costs of bringing its flagship product, an anti-HIV microbicide called 5P12-RANTES, into the clinic.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.